NCT07329166Recruiting
Reducing Mobility-associated Interruption in HIV Treatment in Malawi
Reducing Mobility-associated Interruption in HIV Treatment in Malawi (REMIT): Pilot Trial to Assess Acceptability and Feasibility of a Mobility-specific Intervention Package
Source: ClinicalTrials.gov · Last updated 9 Jan 2026
Brief summary (registry, in English)
The goal of this pilot clinical trial is to assess the feasibility and acceptability of an intervention package designed to reduce mobility-associated interruptions in HIV treatment in people living with HIV in Malawi who are initiating or returning to antiretroviral treatment (ART) after interruption. The main questions it aims to answer are: * Is the intervention acceptable to healthcare workers and ART clients? * Is the intervention feasible in the context of Malawi's health system, and what are the major operational challenges, resource requirements, and implementation barriers? In addition, researchers will compare HIV treatment outcomes (specifically ART retention rates) between intervention and control groups to establish a preliminary estimate of the intervention's efficacy. Participants will complete a survey on the day of enrollment and some participants will complete an in-depth interview and/or a survey after completion of the 6-month follow-up period. Facilities assigned to the intervention group will receive the full package of interventions (training on mobility-specific counseling for counsellors, access to a toll-free hotline for clients and healthcare workers, and training on multi-month dispensing for providers), while facilities assigned to the control group will provide standard of care.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 8 Jan 2026
- Start date
- 18 Dec 2025
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- University of California, Los Angeles
- Diseases
- HIV
- NCT number
- NCT07329166
What you commit to
- Study type: Interventional
- Planned participants: 400
- From 18 Dec 2025 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Attending ART clinic on behalf of someone else (i.e. guardian)
- Attending ART clinic only to obtain emergency refill
- Attending ART clinic for a routine refill without a recent \>=28 days interruption in treatment
- Transferring in to study facility without a preceding interruption in treatment of \>=28 days
Who the study is looking for
- 15 years of age or older
- Living with HIV
- Attending ART clinic to initiate OR re-initiate care:
- Initiate: initiating ART for the first time, per self-report
- Re-initiate: returning to care after missing a refill appointment by \>28 days
Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Partners in Hope Coordinator of this site? Confirm its status | Lilongwe | Malawi | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.